What is Serina Therapeutics, Inc. (SER)?

Serina Therapeutics, Inc. (SER) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of SER?

The current price of SER is $1.94. Prices are updated in real time on Stocks360.

What is SER's price-to-earnings (PE) ratio?

SER's trailing twelve-month PE ratio is -1.03, based on current price and earnings per share data available on Stocks360.

What is SER's market capitalization?

SER's market capitalization is $29,095,150.00, placing it in the small-cap tier.

Serina Therapeutics, Inc. (SER)

Stock analysis · AMEX · Healthcare · Biotechnology

$1.94

Market Cap

$29.10M

PE (TTM)

-1.03

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.03

Day Range

$1.47 – $2.50

52-wk Range

$1.22 – $5.00

Avg Volume

N/A

Volume

154.90K

Serina Therapeutics, Inc. (SER) is a publicly traded company in the Healthcare sector. Latest price: $1.94. Market cap $29.10M. Trailing PE -1.03. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $5.00 2026-10-30 · $1.94 (-61.20%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.55 vs est. $-0.47

Missed by $0.08

Next Earnings

Nov 18, 2026

EPS estimate $-0.34

Proprietary Signals

Signal snapshot temporarily unavailable.

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.03×
P/S (TTM)	0.00×
P/B	1.70×
PEG	0.02×
P/FCF (TTM)	-1.37×
EV / EBITDA	-0.42×
EV / Sales	0.00×
Earnings Yield	-66.62%
Free Cash Flow Yield	-72.77%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$9.28M
Net Income (TTM)	-$19.38M
Free Cash Flow (TTM)	-$20.98M
Net Debt	-$19.82M
Working Capital	$21.27M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-222.42%
Return on Invested Capital	-116.37%